Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.57 |
| ▸ | HTR2C | P28335 | 7/20 | 0.56 |
| ▸ | HTR2B | P41595 | 5/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471115 | 1.00 | PNMT (0.57) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25252543 | 1.00 | PNMT (0.57) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL31528391 | 0.85 | PNMT (0.54) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25266925 | 0.85 | PNMT (0.54) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25212417 | 0.85 | PNMT (0.54) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL1077845 | 0.79 | HTR2C (0.82) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11738740 | 0.78 | HTR2C (0.80) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25590225 | 0.75 | CHRM5 (0.45) | HTR2CHTR2B | |
| SCHEMBL30471102 | 0.74 | PNMT (0.49) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25266762 | 0.74 | PNMT (0.49) | PNMTHTR2CHTR2BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436664-A1 | ANTAGONISTS OF CAV 2.3 | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |